Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

Novel H-2D<sup>b</sup>-restricted CD8 epitope derived from mouse MAGE-type antigen P1A mediates antitumor immunity in C57BL/6 mice.

McAuliffe J. et al, (2024), Journal for immunotherapy of cancer, 12

Tumor monocyte content predicts immunochemotherapy outcomes in esophageal adenocarcinoma.

Carroll TM. et al, (2023), Cancer cell, 41, 1222 - 1241.e7

Intravenous heterologous prime-boost vaccination activates innate and adaptive immunity to promote tumor regression.

Ramirez-Valdez RA. et al, (2023), Cell reports, 42

Tryptophan depletion sensitizes the AHR pathway by increasing AHR expression and GCN2/LAT1-mediated kynurenine uptake, and potentiates induction of regulatory T lymphocytes.

Solvay M. et al, (2023), Journal for immunotherapy of cancer, 11

Tumour immune rejection triggered by activation of α2-adrenergic receptors.

Zhu J. et al, (2023), Nature

Metformin improves cancer immunotherapy by directly rescuing tumor-infiltrating CD8 T lymphocytes from hypoxia-induced immunosuppression.

Finisguerra V. et al, (2023), Journal for immunotherapy of cancer, 11

Multiomics and spatial mapping characterizes human CD8+ T cell states in cancer.

Naulaerts S. et al, (2023), Sci Transl Med, 15

Editorial: Heme proteins: key players in the regulation of immune responses.

Volpi C. et al, (2023), Front Immunol, 14

Combining personalized neoantigen vaccination with chemotherapy and anti-PD-1 to treat NSCLC.

Leung CSK. and Van den Eynde BJ., (2022), Cancer Cell

New Insights into the Mechanisms of Proteasome-Mediated Peptide Splicing Learned from Comparing Splicing Efficiency by Different Proteasome Subtypes.

Ferrari V. et al, (2022), Journal of immunology (Baltimore, Md. : 1950)

T-cell mediated targeted delivery of anti-PD-L1 nanobody overcomes poor antibody penetration and improves PD-L1 blocking at the tumor site

Petit P-F. et al, (2022), Cancer Immunology Research

Targeting an alternate Wilms' tumor antigen 1 peptide bypasses immunoproteasome dependency.

Lahman MC. et al, (2022), Science translational medicine, 14

Navigating Critical Challenges Associated with Immunopeptidomics-Based Detection of Proteasomal Spliced Peptide Candidates

Lichti CF. et al, (2022), Cancer Immunology Research

Functional Differences between Proteasome Subtypes.

Abi Habib J. et al, (2022), Cells, 11

Systemic tryptophan homeostasis.

Klaessens S. et al, (2022), Frontiers in molecular biosciences, 9

Investigation of chalcogen bioisosteric replacement in a series of heterocyclic inhibitors of tryptophan 2,3-dioxygenase.

Kozlova A. et al, (2021), European journal of medicinal chemistry, 227

Heterologous prime-boost vaccination targeting MAGE-type antigens promotes tumor T-cell infiltration and improves checkpoint blockade therapy.

McAuliffe J. et al, (2021), J Immunother Cancer, 9

Rational Design of Original Fused-Cycle Selective Inhibitors of Tryptophan 2,3-Dioxygenase.

Kozlova A. et al, (2021), Journal of medicinal chemistry, 64, 10967 - 10980

Arid5a: A Missing Link between EMT and Tumoral Immune Resistance

Van den Eynde BJ., (2021), Cancer Immunology Research

Tryptophanemia is controlled by a tryptophan-sensing mechanism ubiquitinating tryptophan 2,3-dioxygenase

Klaessens S. et al, (2021), Proceedings of the National Academy of Sciences, 118, e2022447118 - e2022447118

Load More

1
2
3
4
5
6
7
...
»

Include forthcoming?